Q1 2027 Onesource Specialty Pharma Ltd Earnings Call Transcript
Key Points
- OneSource Specialty Pharma Ltd (BOM:544292) reported a strong quarter with revenues reaching 4,490 million Indian rupees, marking a 37% year-on-year growth.
- EBITDA increased significantly by 39% year-on-year, demonstrating strong operational performance.
- The company successfully launched Semagluteet commercially, contributing to revenue growth.
- OneSource expanded its customer base with new MSA contracts and customer wins across various businesses.
- The company is making significant strides in its biologics segment, adding a marquee global biotech major as a partner, which is expected to drive future growth.
- The soft gelatin capsule business has not grown as expected, with capacity utilization issues and delays in tech transfers affecting performance.
- There are concerns about temporary disruptions in supply due to a customer's API manufacturing shutdown, although the company has mitigated this with a diverse customer base.
- The injectable business will experience a temporary shutdown for capacity expansion, which may impact short-term performance.
- Geopolitical issues, such as those in the Middle East, are causing logistical challenges, including increased shipping times and costs.
- The company faces competitive pressures in the biologics CDMO space, with other domestic players entering the market, although it sees this as an opportunity rather than a risk.
Ladies and gentlemen, good day and welcome to One Source Specialty Pharma Limited, Q1 F527 Earnings Conference Call. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal and operate the web everything star and zero on your touchstone phone. Please note that this conference is being recorded. I now hand the conference over to Abhishek.
Thank you and over to you, Abhishek.
Thank you Renju and thank you all for joining us today for the earnings conference call of OneSource Specialty Pharma Limited for Q1 FY27.
We are pleased to have with us Neeraj CEO and MD and Anurag CFO of the company who will walk you through the key business and financial highlights of the quarter.
I trust you have had the opportunity to review our results release and the investor presentation both of which are
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
